Analyzing the atai Life Sciences IPO

50:13
 
Share
 

Manage episode 294575373 series 2738732
By Greg Kubin & Matias Serebrinsky, Greg Kubin, and Matias Serebrinsky. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Today's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO.
In this episode, we discuss:

  • How atai went from idea to IPO in 3 years
  • An overview of atai’s drug development programs and enabling technologies
  • The platform’s strategy and risks

Links to topics in this episode:
Atai life sciences
Etifoxine
Esketamine & arketamine
Atai’s S-1
Psychedelic Pharmacist Association
Calyx Law
Psilocybin Alpha, Noetic Fund
kratom, Salvinorin A, BNC210, mitragynine
Mike Novogratz, Christian Angermayer, George Goldsmith, Ekaterina Malievskaia, Peter Thiel
PureTech Health, Akili Interactive Labs
BT’s DemeRx Episode
Viridia Life Sciences, EmpathBio, Kures, Recognify Life Sciences
Read the transcript here.
Watch episode 9 on YouTube.
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Jonathan Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music: The Innovation by Zack Frank (our very own sound engineer

20 episodes